Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: A pilot study from the pan American collaborative retina study group

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 3, 2013, Pages 366-371

  Wu, Lihteh ^a   Arevalo, J Fernando ^b,c   Hernandez Bogantes, Erick ^a   Regatieri, Caio V ^d   Roca, José A ^e   Farah, Michel E ^d  

^a Instituto de Cirugia Ocular   (Costa Rica)

^b KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e CLÍNICA RICARDO PALMA   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; INFLIXIMAB;

AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOPHTHALMITIS; EXUDATIVE MACULAR DEGENERATION; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE ABNORMALITY; MALE; OUTCOME ASSESSMENT; PILOT STUDY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84876791074     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0203     Document Type: Article

References (35)

1. Ferris, F.L., 3rd, Fine, S.L., and Hyman, L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 102:1640-1642, 1984. (Pubitemid 15204559)
2. Klein, R., Peto, T., Bird, A., and, Vannewkirk, M.R. The epidemiology of age-related macular degeneration. Am. J. Ophthalmol. 137:486-495, 2004. (Pubitemid 38328641)
3. Bressler, N.M., Bressler, S.B., Congdon, N.G., et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch. Ophthalmol. 121:1621-1624, 2003. (Pubitemid 37392370)
4. Brown, D.M., Michels, M., Kaiser, P.K., et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57-65 e5, 2009.
5. Martin, D.F., Maguire, M.G., Ying, G.S., et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364:1897-1908, 2011.
6. Wiedmann, M.W., Mossner, J., Baerwald, C., and Pierer, M. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr. Metab. Immune Disord. Drug Targets 9:295-314, 2009.
7. Maini, R., St. Clair, E.W., Breedveld, F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939, 1999.
8. Olson, J.L., Courtney, R.J., and Mandava, N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch. Ophthalmol. 125:1221-1224, 2007. (Pubitemid 47403029)
9. Regatieri, C.V., Dreyfuss, J.L., Melo, G.B., et al. Dual role of intravitreous infliximab in experimental choroidal neo-vascularization: effect on the expression of sulfated glycosaminoglycans. Invest. Ophthalmol. Vis. Sci. 50:5487-5494, 2009.
10. Wan, L., Lin, H.J., Tsai, Y., et al. Tumor necrosis factor-alpha gene polymorphisms in age-related macular degeneration. Retina 30:1595-1600, 2010.
11. Markomichelakis, N.N., Theodossiadis, P.G., and Sfikakis, P.P. Regression of neovascular age-related macular degeneration following infliximab therapy. Am. J. Ophthalmol. 139:537-540, 2005. (Pubitemid 40379086)
12. Theodossiadis, P.G., Liarakos, V.S., Sfikakis, P.P., et al. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am. J. Ophthalmol. 147:825-830, 830.e1, 2009.
13. Giganti, M., Beer, P.M., Lemanski, N., et al. Adverse events after intravitreal infliximab (Remicade). Retina 30:71-80, 2010.
14. Tsilimbaris, M., Diakonis, V.F., Naoumidi, I., et al. Evaluation of potential retinal toxicity of adalimumab (humira). Graefes Arch. Clin. Exp. Ophthalmol. 247:1119-1125, 2009.
15. Manzano, R.P., Peyman, G.A., Carvounis, P.E., et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch. Clin. Exp. Ophthalmol. 246:907-911, 2008.
16. Penfold, P.L., Killingsworth, M.C., and Sarks, S.H. Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch. Clin. Exp. Ophthalmol. 223:69-76, 1985. (Pubitemid 15051681)
17. Klein, R.J., Zeiss, C., Chew, E.Y., et al. Complement factor H polymorphism in age-related macular degeneration. Science 308:385-389, 2005. (Pubitemid 40530070)
18. Hageman, G.S., Anderson, D.H., Johnson, L.V., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U S A 102:7227-7232, 2005. (Pubitemid 40696361)
19. Edwards, A.O., Ritter, R., 3rd, Abel, K.J., et al. Complement factor H polymorphism and age-related macular degeneration. Science 308:421-424, 2005. (Pubitemid 40530082)
20. Nussenblatt, R.B., and Ferris, F., 3rd. Age-related macular degeneration and the immune response: implications for therapy. Am. J. Ophthalmol. 144:618-626, 2007.
21. Anderson, D.H., Mullins, R.F., Hageman, G.S., and Johnson, L.V. A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 134:411-431, 2002.
22. Hageman, G.S., Luthert, P.J., Victor Chong, N.H., et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 20:705-732, 2001. (Pubitemid 32918285)
23. Apte, R.S., Richter, J., Herndon, J., and Ferguson, T.A. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med. 3:e310, 2006.
24. Ambati, J., Anand, A., Fernandez, S., et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 9:1390-1397, 2003. (Pubitemid 37466188)
25. Espinosa-Heidmann, D.G., Suner, I.J., Hernandez, E.P., et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44:3586-3592, 2003. (Pubitemid 36909799)
26. Cousins, S.W., Espinosa-Heidmann, D.G., and Csaky, K.G. Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? Arch. Ophthalmol. 122:1013-1018, 2004. (Pubitemid 39037966)
27. Giansanti, F., Ramazzotti, M., Vannozzi, L., et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest. Ophthalmol. Vis. Sci. 49:1151-1156, 2008.
28. Theodossiadis, P.G., Liarakos, V.S., Sfikakis, P.P., et al. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch. Clin. Exp. Ophthalmol. 247:273-281, 2009.
29. Arias, L., Caminal, J.M., Badia, M.B., et al. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina 30:1601-1608, 2010.
30. Nussenblatt, R.B., Byrnes, G., Nida, H., et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neo-vascularization. Retina 30:1579-1587, 2010.
31. Androudi, S., Tsironi, E., Kalogeropoulos, C., et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 117:1612-1616, 2010.
32. Schachat, A.P., Chambers, W.A., Liesegang, T.J., and Albert, D.A. Safe and effective. Ophthalmology 110:2073-2074, 2003. (Pubitemid 37337840)
33. Joussen, A.M., Doehmen, S., Le, M.L., et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis 15:1418-1428, 2009.
34. Joussen, A.M., Poulaki, V., Mitsiades, N., et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16:438-440, 2002.
35. Pulido, J.S., Pulido, J.E., Michet, C.J., and Vile, R.G. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Retina 30:1-5, 2010.